UserGems
AutomatedSales intelligence that tracks job changes of past customers
UserGems has 3 plans: paid plans from $3,333/month. The last price change we recorded was on 9 September 2026.
UserGems plans and prices
Core
monthly$3,333/mo
- monthly$3,333/mo($2,750/month ($33k/year))
- yearly$3,333.33/mobilled annually ($40,000/yr)
- 3 admin users, 20 end users
- 30,000 tokens
- Build list: create and enrich
- Prioritize: account and lead scoring
- Automated campaigns and AI Chrome Extension
Advanced
monthly$6,250/mo
- monthly$6,250/mo($6,250 / month)
- yearly$6,250/mobilled annually ($75,000/yr)
- Admin users — Unlimited
- End users — Unlimited
- Credits — 10,000,000 - 100K data actions or - 1M AI actions - TAM coverage: 4-10k accounts
- Build List (create & enrich)
- Account & Contact Scoring
- Automated Campaigns
- Writing Agent
- Research Agent
Show all 30 featuresShow fewer
- AI Co-pilot
- Chrome Extension
- UserGems MCP
- Ad Audience Sync
- Calendar Capture
- Contact-level Intent & Web Deanonymization
- Buying Stages
- CRM Hygiene
- CRM (Salesforce, Hubspot)
- Sales Engagement (Outreach, Salesloft, Gong Engage)
- Ad Platforms (Linkedin, Meta, Google)
- Reporting & Analytics
- Single Sign On
- Custom Integrations
- Salesforce Sandbox
- UserGems Sponsored SPIFF — $500
- Email & Slack Support
- Implementation & Customer Success — Advanced support
- Non-standard Legal & Security Review
- results guaranteed
- Revenue Guaranteed — 2x ROI
- Implementation — $5k
Elite
monthly$12,500/mo
- monthly$12,500/mo($10,000/month ($120k/year))
- yearly$12,500/mobilled annually ($150,000/yr)
- 10 admin users, 100 end users
- 180,000 tokens
- Custom research agent and closed lost research
- Ad audience sync and buying stages
- 3x ROI revenue guarantee
Price history
Last 2 recorded changes
$2,750→$3,333(+21.2%)
| Date | Plan | Change | Old | New | Δ% |
|---|---|---|---|---|---|
| Sep 9, 2026 | Elite | Increase | $10,000 | $12,500 | +25.0% |
| Sep 9, 2026 | Core | Increase | $2,750 | $3,333 | +21.2% |
Other Sales products
No confirmed alternatives yet.